The Parkinson's disease nurse specialist and subcutaneous apomorphine infusion. A Scoping Review of the literature

Luana Conte; Pierluigi Lezzi; Roberto Lupo; Antonio Fasano; Maicol Carvello; Tania Lezzi; Giovanna Artioli; Elsa Vitale; Ivan Rubbi; Giorgio De Nunzio

doi:10.23750/abm.v95i6.15908

The Parkinson's disease nurse specialist and subcutaneous apomorphine infusion. A Scoping Review of the literature

Authors

Luana Conte Department of Physics and Chemistry, University of Palermo, Palermo, Italy
Pierluigi Lezzi “Veri Velli Ponti” Hospital, Scorrano, Local Health Authority Lecce, Italy
Roberto Lupo “San Giuseppe da Copertino” Hospital, Local Health Authority of Lecce, Lecce, Italy.
Antonio Fasano “Vito Fazzi” Hospital, Local Health Authority of Lecce, Lecce, Italy.
Maicol Carvello Community Hospital, Local Health Authority of Romagna, Italy
Tania Lezzi “Santissima Annunziata” Hospital, Local Health Authority of Taranto, Taranto, Italy
Giovanna Artioli University of Parma, Parma, Italy
Elsa Vitale Department of Mental Health, Local Healthcare Authority of Bari, Italy
Ivan Rubbi School of Nursing, University of Bologna
Giorgio De Nunzio Laboratory of Biomedical Physics and Environment, Department of Mathematics and Physics "E. De Giorgi", University of Salento, Lecce, Italy

DOI: https://doi.org/10.23750/abm.v95i6.15908

Keywords:

subcutaneous apomorphine infusion therapy; , Parkinson’s disease; , Parkinson's disease nurse specialists (PDNS);

Abstract

Objective: The aim of this scoping review is to outline the scientific evidence concerning the role of Parkinson's disease nurse specialists (PDNS) to provide education and guidance to patients with Parkinson's disease (PD) undergoing subcutaneous apomorphine therapy (CSAI).

Introduction: PD affects approximately 1% of both men and women on a global scale, especially those aged 60 and above. Working within a multidisciplinary team, the PDNS enhances adherence to the treatment regimen, even in a home-based setting.

Inclusion criteria: Included studies involved participants over 18 years old, with texts in English or Italian. Exclusions covered research on alternative apomorphine administrations, brain stimulation, comparisons with other treatments, mood changes from apomorphine, or unrelated to PDNS training.

Methods: We conducted a comprehensive literature review across databases such as Medline (via PubMed), The Cochrane Library, Scopus, Web of Science (WOS), and Google Scholar, sourcing relevant articles to identify primary indexed studies examining the interaction between nurse practitioners and PD patients undergoing subcutaneous apomorphine treatment.

Results. The review encompasses twenty studies, revealing that specialized nursing education and training during the subcutaneous apomorphine therapy phase can effectively mitigate the considerable risks associated with treatment nonadherence.

Conclusions: The collaboration of proficient and specialized nursing personnel, working alongside a multidisciplinary team, to deliver suitable training and education during CSAI, is instrumental in averting adverse outcomes and potential nonadherence issues, thereby enhancing the quality of life for both PD patients and their caregivers.

References

Lezzi P, Lupo R, Lezzi T, et al. The Prephase Nursing in Levodopa Carbidopa Intestinal Gel Therapy. J Neurosci Nurs 2022;54(5):215–219; doi: 10.1097/JNN.0000000000000671.

Lees A, Turner K. Apomorphine for Parkinson’s Disease. Pract Neurol 2002;2(5):280–287; doi: 10.1046/j.1474-7766.2002.00086.x.

Tsai W-L, Chen H-Y, Huang Y-Z, et al. Long-Term Voluntary Physical Exercise Exerts Neuroprotective Effects and Motor Disturbance Alleviation in a Rat Model of Parkinson’s Disease. Behav Neurol 2019;2019:1–10; doi: 10.1155/2019/4829572.

Nijhuis FAP, van Heek J, Bloem BR, et al. Choosing an Advanced Therapy in Parkinson’s Disease; is it an Evidence-Based Decision in Current Practice? J Parkinsons Dis 2016;6(3):533–543; doi: 10.3233/JPD-160816.

Tyne HL, Parsons J, Sinnott A, et al. A 10 year retrospective audit of long-term apomorphine use in Parkinson?s disease. J Neurol 2004;251(11):1370–1374; doi: 10.1007/s00415-004-0547-4.

Karni L, Jusufi I, Nyholm D, et al. Toward Improved Treatment and Empowerment of Individuals With Parkinson Disease: Design and Evaluation of an Internet of Things System. JMIR Form Res 2022;6(6):e31485; doi: 10.2196/31485.

Bhidayasiri R, Boonpang K, Jitkritsadakul O, et al. Understanding the role of the Parkinson’s disease nurse specialist in the delivery of apomorphine therapy. Parkinsonism Relat Disord 2016;33:S49–S55; doi: 10.1016/j.parkreldis.2016.11.014.

Özkan S, Erer S, Elibol B, et al. Apomorphine in the Treatment of Parkinson’s Disease. Turkish J Neurol 2021;27(4):358–365; doi: 10.4274/tnd.2021.06706.

De Rosa A, Tessitore A, Bilo L, et al. Infusion treatments and deep brain stimulation in Parkinson’s Disease: The role of nursing. Geriatr Nurs (Minneap) 2016;37(6):434–439; doi: 10.1016/j.gerinurse.2016.06.012.

Kaiyrzhanov R, Rizig M, Aitkulova A, et al. Parkinson’s Disease in Central Asian and Transcaucasian Countries: A Review of Epidemiology, Genetics, Clinical Characteristics, and Access to Care. Parkinsons Dis 2019;2019:1–7; doi: 10.1155/2019/2905739.

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339(jul21 1):b2700–b2700; doi: 10.1136/bmj.b2700.

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;n71; doi: 10.1136/bmj.n71.

Marsili L, Bologna M, Miyasaki JM, et al. Device-aided therapies for advanced Parkinson disease: insights from an international survey. Neurol Sci 2021;42(7):2961–2964; doi: 10.1007/s10072-021-05106-4.

Henriksen T, Staines H. Continuous Subcutaneous Apomorphine Infusion in Parkinson’s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation. J Pers Med 2021;11(6):525; doi: 10.3390/jpm11060525.

Bhidayasiri R, Chaudhuri KR, LeWitt P, et al. Effective Delivery of Apomorphine in the Management of Parkinson Disease. Clin Neuropharmacol 2015;38(3):89–103; doi: 10.1097/WNF.0000000000000082.

Katzenschlager R, Poewe W, Rascol O, et al. Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord 2021;83:79–85; doi: 10.1016/j.parkreldis.2020.12.024.

Agbo F, Isaacson SH, Gil R, et al. Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study. Neurol Ther 2021;10(2):693–709; doi: 10.1007/s40120-021-00251-6.

Nigro S, Bordier C, Cerasa A, et al. Apomorphine-induced reorganization of striato-frontal connectivity in patients with tremor-dominant Parkinson’s disease. Parkinsonism Relat Disord 2019;67:14–20; doi: 10.1016/j.parkreldis.2019.09.006.

Bhidayasiri R, Garcia Ruiz PJ, Henriksen T. Practical management of adverse events related to apomorphine therapy. Parkinsonism Relat Disord 2016;33:S42–S48; doi: 10.1016/j.parkreldis.2016.11.017.

Caughman CY, Factor S. A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson’s disease ‘OFF’ episodes. Expert Rev Neurother 2021;21(2):169–177; doi: 10.1080/14737175.2020.1855145.